Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03923231
Other study ID # VirTUAL WP5
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2, 2019
Est. completion date November 30, 2022

Study information

Verified date May 2023
Source University of Liverpool
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The lack of data relating to the DDI between ATV and RIF is a major limitation to the use of ATV in patients who require treatment for TB. The VirTUAL Workpackage 2 will explore the necessary dose escalation required to overcome this interaction in non-pregnant HIV-infected adults who are virologically suppressed on bPI-based ART, and who are administered RIF as a study drug, not as part of a full TB treatment regimen. As the specific objective of WP2 is to define the dose of ATV, participants taking an alternative bPI will be transitioned to ATV for the duration of that study. However, to extrapolate the results of this study to special populations such as pregnant and postpartum women, children and adolescents and those with other 'special' characteristics such as obesity (BMI >30 Kg/m2) or malnutrition (BMI <18.5 Kg/m2) we propose to undertake sparse sampling for pharmacokinetic analysis from individuals who require ATV-based ART for their clinical care. Sparse PK data will be obtained opportunistically from participants in the 'special populations' defined above who are receiving ATV as part of their routine clinical care. Subjects will be identified from clinics including the Joint Clinical Research Center (JCRC) and Infectious Diseases Institute (IDI), Kampala, and from sites including Groote Schuur Hospital and Gugulethu Community Health Centre, Cape Town. The ATV/r data from "special populations" will enable validation and refinement of both the PBPK model (WP1) and the pop-PK models (WP4) of the VirTUAL consortium.


Description:

Overview of VirTUAL Consortium Through the VirTUAL Consortium, the investigators aim to define the optimal use of second-line ART regimens in vulnerable populations with TB co-infection. The primary objective is to 'to determine the optimal dose of boosted atazanavir (ATV/r) when used in combination with RIF-based TB treatment in children, adolescents and pregnant or breastfeeding women.' The results from this protocol (VirTUAL WP5) will be considered in the context of the full research programme. This can be summarised as follows: Physiologically-based pharmacokinetic (PBPK) modelling will be developed to understand bPI and RIF Drug-Drug Interactions (DDIs), identifying potential dosing strategies to overcome these in adults and special populations (WP1). This data will inform clinical pharmacokinetic studies exploring the necessary dose escalation of ATV/r, including in the context of high-dose RIF, performed in Kampala (WP2). Intracellular pharmacokinetics will further characterise the DDI (WP3). PBPK and population pharmacokinetics (pop-PK) modelling will be integrated enabling extrapolation to special populations (WP4), and sparse data collection from such populations receiving different combinations of second-line ART and/or TB treatment in Kampala and Cape Town will validate and refine these models (WP5). Capacity building focussing on equipping African scientists with the tools to efficiently define drug dosing in complex populations (WP6), communication and stakeholder engagement (WP7) will increase the application of this methodology to other priority research into pharmacokinetics in special populations. This protocol describes the sparse pharmacokinetic sampling component which forms Workpackage 5 (WP5) of this research programme. The dose-escalation study (WP2) is an interventional trial which will be conducted in 28 healthy, virologically suppressed volunteers who are on ATV-based second-line ART, are aged over 18, have a normal BMI and are not pregnant or breastfeeding, and which will take place at JCRC, Kampala, Uganda. This study is anticipated to commence in mid-2019, and will explore in detail the changes in pharmacokinetics of ATV/r in both plasma and within cells which take place when rifampicin is co-administered, and will evaluate the necessary dose adjustment which is required to concurrently administer ATV/r with rifampicin-based TB treatment. WP2 will generate intensive data on these 28 well characterized individuals who do not have 'special' characteristics. However, there is a paucity of data on ATV/r disposition in patients who are typically excluded from clinical trials, and therefore the observational data from WP5 will be collected from individuals who fall into the listed categories of special populations and who are being treated with ATV/r for their own health. Data from either WP2 or WP5 alone will be amenable to pharmacometric analysis and bring value, but the combined modelling approach using both sets of data in a combined model will allow the most comprehensive evaluation of ATV/r disposition in the wider population, and will enable projections of dosing recommendations for the special populations who require concurrent treatment for TB whilst receiving ATV/r-based ART. Individuals will be identified at routine clinic appointments. They (or their guardians) will be asked to keep a detailed record of dosing times for three to five days prior to their study appointment at which sampling will be performed. If they take their medication in the morning, they will be asked to bring the medication to clinic for observation of dosing. Repeat sampling at subsequent appointments will enable assessment of both between and within-individual variability, for example during periods of rapid childhood growth or during pregnancy and transition back to non-pregnant physiological state. It is aimed to obtain 20 sparse PK profiles in each of the following groups (pregnant, child <5, child 6-11, adolescent 12-18, obese (BMI >30 Kg/m2), malnourished (BMI <18.5 Kg/m2)), with each individual contributing 4 samples per PK visit, and possibly followed up longitudinally during the study (each individual may attend for a maximum of three study visits). Therefore there will be between 7 (6 participants being sampled on 3 occasions and a final participant sampled on 2 occasions) and 20 (if each participant was only sampled on a single occasion) individual participants per group to generate the 20 sampling 'occasions', with a total number of participants across the six groups included in the study of between 42 and 120. This will provide an essential clinical dataset to inform the pop-PK modelling approach and validate the PBPK simulations, describing exposure and pharmacokinetic variability in the populations of interest. The data from this work package will be pooled with the data from the study in volunteers and jointly analysed using PK modelling. Differences in the PK parameters for each of the groups will be investigated. There exist no peer-reviewed published data regarding the transfer of ATV/r into breast milk. Therefore, among women who are enrolled during pregnancy and followed into the postpartum phase, paired breast milk samples will be obtained at the same time as plasma samples.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date November 30, 2022
Est. primary completion date May 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the participant (or a legal representative) has been informed of all pertinent aspects of the study. 2. In a child aged =7 years (South Africa) or aged =8 years (Uganda), evidence of assent to participate 3. Participants who are willing and able to comply with scheduled visits, laboratory tests, and other study procedures. 4. HIV-infected, receiving ATV-based ART treatment OR HIV-infected receiving second-line ART with concurrent rifamycin-based TB treatment 5. Participant is within one of the target populations: 1. Pregnant (>20 weeks) 2. Body mass index >30 or <18.5 Kg/m2 3. Child or adolescent aged <18 years Exclusion Criteria: 1. Medical, psychiatric or obstetric condition that might affect participation in the stuy based on investigator judgement 2. Dissent from a minor 3. For pregnant women in Uganda, where the husband is reasonably involved, paternal objection

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atazanavir 300mg/ Ritonavir 100 mg once daily
There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
Atazanavir 250 mg / ritonavir 80 mg
There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg

Locations

Country Name City State
South Africa Desmond Tutu HIV Foundation Cape Town Western Cape
South Africa University of Cape Town Cape Town Western Cape
Uganda Infectious Diseases Institute Kampala
Uganda Joint Clinical Research Centre Kampala

Sponsors (6)

Lead Sponsor Collaborator
University of Liverpool Desmond Tutu HIV Foundation, European and Developing Countries Clinical Trials Partnership (EDCTP) - funder, Infectious Diseases Institute, Makerere University College of Health Sciences, Joint Clinical Research Centre- Kampala, University of Cape Town

Countries where clinical trial is conducted

South Africa,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Other Modelling of atazanavir pharmacokinetics To use nonlinear mixed-effects modelling to describe sources of variability on the pharmacokinetics of ATV 4 years
Other Exploratory objective: Cmax of second-line ART with TB treatment To describe the maximum concentrations of second-line antiretroviral drugs and rifamycin-containing TB therapy in HIV-infected pregnant and postpartum women, children and adolescents and individuals with extremes of BMI 3 years
Other Exploratory objective: AUC of second-line ART with TB treatment To describe the area under the concentration-time curve of second-line antiretroviral drugs and rifamycin-containing TB therapy in HIV-infected pregnant and postpartum women, children and adolescents and individuals with extremes of BMI 3 years
Other Exploratory objective: Ctau of second-line ART with TB treatment To describe the minimum concentration of second-line antiretroviral drugs and rifamycin-containing TB therapy in HIV-infected pregnant and postpartum women, children and adolescents and individuals with extremes of BMI 3 years
Primary Atazanavir Cmax To describe the maximum concentration of atazanavir reached after dosing in the different groups 3 years
Primary Atazanavir AUC0-24 To describe the area under the concentration-time curve from 0 to 24 hours after dosing in the different groups 3 years
Primary Atazanavir Ctau To describe the trough concentration of atazanavir after dosing in the different study groups 3 years
Secondary Comparison of geometric mean of atazanavir Cmax with healthy adult population To compare atazanavir Cmax with typical healthy individuals treated with atazanavir who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme 3 years
Secondary Comparison of geometric mean of atazanavir AUC0-24 with healthy adult population To compare atazanavir AUC0-24 with that of typical healthy adults treated with atazanavir-based ART who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme 3 years
Secondary Comparison of geometric mean of atazanavir Ctau with healthy adult population To compare atazanavir Ctau with that of typical healthy adults treated with atazanavir-based ART who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2